{"id":781273,"date":"2023-08-31T07:52:45","date_gmt":"2023-08-31T11:52:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-reports-six-month-financial-results-for-2023-and-provides-corporate-update\/"},"modified":"2023-08-31T07:52:45","modified_gmt":"2023-08-31T11:52:45","slug":"adagene-reports-six-month-financial-results-for-2023-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-reports-six-month-financial-results-for-2023-and-provides-corporate-update\/","title":{"rendered":"Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update"},"content":{"rendered":"
\n

\n – Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where CTLA-4-mediated Treg depletion is essential for efficacy \u2013<\/em>
\n \n <\/p>\n

\n – Strong efficacy signal observed in MSS CRC phase 2 single arm study for SAFEbody\u00ae<\/sup> ADG126 in combination with pembrolizumab at the 10 mg\/kg every three weeks dosing regimen –<\/em>\n <\/p>\n

\n – Advancing MSS CRC cohort with ten more patients at the active every three weeks dosing regimen for SAFEbody ADG126 plus pembrolizumab following Simon\u2019s two-stage statistical design \u2013 <\/em>\n <\/p>\n

\n – Roche initiates randomized phase 1b\/2 trial with SAFEbody ADG126 in novel triple combination<\/em>
\n
\n for first-line hepatocellular carcinoma –<\/em>\n <\/p>\n

\n – Cash balance of US$128.8 million supports operations to late 2025 \u2013<\/em>\n <\/p>\n

SAN DIEGO and SUZHOU, China, Aug. 31, 2023 (GLOBE NEWSWIRE) — Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today reported financial results for the six months ended June 30, 2023 and provided corporate updates.<\/p>\n

\u201cOur anti-CTLA-4 clinical programs demonstrate that an enhanced therapeutic index is capable of unleashing the clinical potential of CTLA-4 treatment, with the right dosing regimens, as a cornerstone in combination with PD-1 and beyond,\u201d said Peter Luo, Ph.D., Chairman, CEO and President of R&D at Adagene. \u201cWe have observed impressive clinical responses in the initial basket trial for ADG126 plus PD-1 therapy in patients where CTLA-4-mediated Treg depletion is essential for efficacy, including cold tumors such as MSS CRC, PD-L1 low expressing and PD-1 resistant warm tumors, enabled by our safety profile for higher, more frequent and repeat dosing.\u201d<\/p>\n

He continued, \u201cThis safety and efficacy profile allows us to evaluate ADG126 plus pembrolizumab in a homogenous patient group for the first time in advanced\/metastatic MSS CRC patients, following Simon\u2019s two-stage statistical design for a single arm phase 2 trial. We are very excited to observe a strong efficacy signal in the first stage and we are now enrolling patients in the second stage with the active dose of ADG126 10 mg\/kg every three weeks. We are optimistic about our ability to push the boundaries of CTLA-4 therapy to improve cancer care.\u201d<\/p>\n

\n ANTI-CTLA-4 HIGHLIGHTS <\/strong>\n <\/p>\n